Kyntra Bio Guides Q4 Loss of $3.89; Revenues Slump 49%, EPS Beat Odds +24%
Kyntra Bio is scheduled to publish its fourth quarter and full-year 2025 financial results on March 16 after market close, followed by a conference call. Analysts expect a $3.89 per share loss on $1.6 million revenues (down 49% year-over-year) and a 24.07% Earnings ESP indicates a likely EPS beat.
1. Upcoming Earnings Release
Kyntra Bio will announce fourth quarter and full-year 2025 financial results on Monday, March 16 after market close, followed by a conference call at 5:00 PM Eastern Time where management will discuss corporate performance and field questions from investors.
2. Analyst Expectations
Wall Street consensus forecasts a loss of $3.89 per share on revenues of $1.6 million, representing year-over-year declines of 94.5% in EPS and 49% in revenue; consensus EPS estimates have held steady over the past 30 days.
3. Earnings ESP and Beat History
The Most Accurate Estimate exceeds the consensus by 24.07%, and with a Zacks Rank of #3, the model suggests a strong probability of an EPS beat, building on a prior quarter surprise of +59.85% when actual loss was $1.61 versus an expected $4.01.